Jon Faldasz/LinkedIn
Nov 21, 2025, 08:55
Jon Faldasz: Why Aren’t We Better at Achieving Therapeutic Warfarin Control?
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Ok I know warfarin is the stinky kid in the corner, but it’s not going anywhere. So why aren’t we better at achieving time in therapeutic range?
Could it be:
– We think that 40% time in range is “good enough”? (data argues otherwise)
– Low warfarin use means we think this problem isn’t significant (patients would argue otherwise)
– We think that the problem is unsolvable? (Anticoagulation specialists argue otherwise)
I would love to get some comments to bring with me to the Anticoagulation Forum Stewardship Summit. Don’t make me call you out, people.”
Stay updated with Hemostasis Today.
-
Apr 12, 2026, 17:34Caitlin Raymond: Granulocyte Transfusions for the Overworked Fellow
-
Apr 12, 2026, 17:33Augustina Isioma Ikusemoro: ABO Typing Is Not the Same in Infants and Adults
-
Apr 12, 2026, 17:32Bastu Odoka: Same Blood Group Does Not Guarantee Compatibility
-
Apr 12, 2026, 17:31Jack Hadfield: SARS-CoV-2–Associated Lasting Mitochondrial Injury in Cardiomyocytes
-
Apr 12, 2026, 17:30Flora Peyvandi: ABB Milan Presentations During the ISTH 2026
-
Apr 12, 2026, 17:01Hafiz Saad Ullah: Introducing to Fully Automatic Peripheral Blood Smear Stainer
-
Apr 12, 2026, 16:53Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
-
Apr 12, 2026, 16:36Piotr Czempik: Patient Blood Management Means Safer Care, Better Quality, and Responsible Resource Use
-
Apr 12, 2026, 16:31Eishi Asano: Available Evidence and Unmet Needs in EEG Use During Stroke Management